Literature DB >> 18230040

Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition.

Sherry P Smith1, Amee R Manges, Lee W Riley.   

Abstract

BACKGROUND: The changing prevalence of drug-resistant community-acquired urinary tract infection (UTI) is often attributed to local antimicrobial drug use or prescribing practices. However, recent molecular epidemiologic studies of community-acquired UTI suggest that other factors may play a greater role.
METHODS: We conducted a multiyear, cross-sectional study to characterize temporal changes in the prevalence of drug-resistant community-acquired UTI at a university community in California. During four 3.5-month sampling periods, urine samples from patients consecutively presenting to the university health service with symptoms of UTI were cultured for Escherichia coli. Antimicrobial susceptibility and genotyping tests of the E. coli isolates were performed.
RESULTS: We recovered 780 E. coli isolates from 1667 patients with UTI. The prevalence of trimethoprim-sulfamethoxazole, ciprofloxacin, and nitrofurantoin resistance showed no trend over the 4 periods. The prevalence of ampicillin resistance decreased significantly over the last 2 study periods. A single clonal group accounted for 75% of this decrease. Enterobacterial repetitive intergenic consensus 2 PCR-based genotyping revealed that only 4 large clonal groups accounted for 52% of the UTIs resistant to trimethoprim-sulfamethoxazole, ciprofloxacin, or nitrofurantoin. No initially pansusceptible clonal groups gained resistance over time.
CONCLUSIONS: This study revealed no obvious trend in the prevalence of drug-resistant community-acquired UTI in a single community. Prevalence at any time was influenced by a small number of E. coli clonal groups. This observation suggests that the introduction of strains that are drug resistant into a community plays a greater role in changing the prevalence of drug-resistant UTI than does the drug use or prescribing habits in that community.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230040     DOI: 10.1086/527386

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Persistent Pandemic Lineages of Uropathogenic Escherichia coli in a College Community from 1999 to 2017.

Authors:  Reina Yamaji; Julia Rubin; Erika Thys; Cindy R Friedman; Lee W Riley
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

2.  Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections.

Authors:  Sheila Adams-Sapper; Binh An Diep; Francoise Perdreau-Remington; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 3.  Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group.

Authors:  Irene Alberici; Aysun Karabay Bayazit; Dorota Drozdz; Sevinç Emre; Michel Fischbach; Jérôme Harambat; Augustina Jankauskiene; Mieczyslaw Litwin; Sevgi Mir; William Morello; Amira Peco-Antic; Peter Sallay; Lale Sever; Giacomo D Simonetti; Przemyslaw Szczesniak; Ana Teixeira; Enrico Vidal; Elke Wuehl; Otto Mehls; Lutz T Weber; Franz Schaefer; Giovanni Montini
Journal:  Eur J Pediatr       Date:  2014-11-28       Impact factor: 3.183

4.  Rapid Emergence, Subsidence, and Molecular Detection of Escherichia coli Sequence Type 1193-fimH64, a New Disseminated Multidrug-Resistant Commensal and Extraintestinal Pathogen.

Authors:  James R Johnson; Brian D Johnston; Stephen B Porter; Connie Clabots; Tricia L Bender; Paul Thuras; Darren J Trott; Rowland Cobbold; Joanne Mollinger; Patricia Ferrieri; Sarah Drawz; Ritu Banerjee
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

5.  Genotypic analysis of uropathogenic Escherichia coli to understand factors that impact the prevalence of β-lactam-resistant urinary tract infections in a community.

Authors:  Nicole J Tarlton; Charles Moritz; Sheila Adams-Sapper; Lee W Riley
Journal:  J Glob Antimicrob Resist       Date:  2019-03-11       Impact factor: 4.035

6.  An Enzyme-Mediated Amplification Strategy Enables Detection of β-Lactamase Activity Directly in Unprocessed Clinical Samples for Phenotypic Detection of β-Lactam Resistance.

Authors:  Tara R deBoer; Nicole J Tarlton; Reina Yamaji; Sheila Adams-Sapper; Tiffany Z Wu; Santanu Maity; Giri K Vesgesna; Corinne M Sadlowski; Peter DePaola; Lee W Riley; Niren Murthy
Journal:  Chembiochem       Date:  2018-09-26       Impact factor: 3.164

7.  European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis.

Authors:  Simone Cagnacci; Laura Gualco; Eugenio Debbia; Gian Carlo Schito; Anna Marchese
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

8.  Association between antimicrobial consumption and resistance in Escherichia coli.

Authors:  Miika Bergman; Solja T Nyberg; Pentti Huovinen; Pirkko Paakkari; Antti J Hakanen
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

9.  Clonal composition of Escherichia coli causing community-acquired urinary tract infections in the State of Rio de Janeiro, Brazil.

Authors:  Rubens C S Dias; Denise V Marangoni; Sherry P Smith; Elizabeth M Alves; Flavia L P C Pellegrino; Lee W Riley; Beatriz M Moreira
Journal:  Microb Drug Resist       Date:  2009-12       Impact factor: 3.431

10.  Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007.

Authors:  Majdi N Al-Hasan; Brian D Lahr; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  J Antimicrob Chemother       Date:  2009-05-12       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.